Dementia Drugs Market, by Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, and Glutamate Inhibitors), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Mi

Dementia Drugs Market, by Drug Class (MAO Inhibitors, Cholinesterase Inhibitors, and Glutamate Inhibitors), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Dementia is a form of disease that affects the functioning of the brain resulting in decline in memory or other thinking skills. Alzheimer’s disease is the most common and largest form of dementia (in over 60% cases), which is observed among people aged 65 years and above. Dementia results from a variety of diseases and injuries that primarily or secondarily affect the brain, such as Alzheimer's disease or stroke. It affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment. The impairment in cognitive function is commonly accompanied, and occasionally preceded, by changes in mood, emotional control, behavior, or motivation. Accumulation of a protein called beta amyloid in the spaces between nerve cells due to genetic mutation is a major cause of dementia. Although dementia is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop therapies centered on the role of beta-amyloid in dementia.

Market Dynamics

Increasing product approval by regulatory authorities is the major driving factor for growth of the dementia drugs market. For instance, on June 24, 2021, Eli Lilly and Company, a pharmaceutical company announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's investigational antibody therapy for Alzheimer's disease (AD). The Breakthrough Therapy designation aims to expedite development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over already available therapies that have received full FDA approval. Dementia due to Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of all cases.

Key features of the study:

• This report provides an in-depth analysis of the global dementia drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dementia drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market

Detailed Segmentation:

• Global Dementia Drugs Market, By Drug Class:
• MAO Inhibitors
• Cholinesterase Inhibitors
• Glutamate Inhibitor
• Global Dementia Drugs Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Others
• Global Dementia Drugs Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Eisai, Inc. *
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Janssen Pharmaceuticals, Inc.
• Biogen Pharmaceuticals
• Forest Laboratories, Inc.
• Eli Lilly and Company
• Novartis AG
• Sanofi S.A.
• AstraZeneca GmbH
• Hoffmann-La Roche
• Merck & Co., Inc.
• Valeant Pharmaceutical International
• Pfizer Inc.
• Teva Pharmaceuticals Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.